Full FDA approval pathway for vaccines and biological products.
A Biologics License Application (BLA) is the formal submission a vaccine manufacturer makes to the FDA to request full approval — also called licensure — for a biological product. A BLA is distinct from an Emergency Use Authorization (EUA): it represents full FDA approval based on complete clinical trial data and comprehensive manufacturing review.
All vaccines currently on the routine U.S. childhood immunization schedule have received full BLA approval. BLA approval is the gold standard for vaccine authorization.
A BLA requires complete clinical trial data including at least 6 months of safety follow-up data, full efficacy results, and manufacturing consistency data from multiple production lots.
BLA approval includes a comprehensive inspection of all manufacturing facilities by FDA investigators. Manufacturing processes must be validated, consistent, and capable of producing the product to specification at commercial scale.
BLA approval results in full prescribing information (package insert) rather than the shorter Fact Sheet required for EUA products. The package insert includes complete clinical trial data, contraindications, adverse event rates, and dosing guidance.
BLA approval grants the manufacturer a license to commercially distribute the product. It triggers full liability provisions and removes EUA-specific informed consent requirements. The product may be mandated by employers, schools, and government entities without the legal complications of EUA status.
Manufacturers typically hold a pre-BLA meeting with FDA to align on the data package required. This meeting establishes what clinical evidence will be needed for approval.
The manufacturer submits the complete BLA — typically hundreds of thousands of pages — covering clinical trial results, manufacturing data, proposed labeling, and post-market surveillance plans.
The FDA's standard review timeline for a BLA is 12 months (or 6 months for priority review). The FDA may convene its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for independent expert review.
The FDA issues either an approval letter (granting the BLA), a complete response letter (requesting additional data or changes), or a refusal to file (if the application is inadequate). Approval is product-specific and indication-specific.
BLA approval does not end FDA oversight:
Received full BLA approval on August 23, 2021 for individuals 16 years and older. Separate BLA approvals followed for younger age groups.
Received full BLA approval on January 31, 2022 for individuals 18 years and older.
Received full BLA approval on May 20, 2024 for individuals 12 years and older.
Has not received full BLA approval as of 2023; remains under EUA with restricted use.
Learn about how the FDA CBER regulates vaccines and biologics in the United States.
Understanding EUA — the emergency authorization pathway used during the COVID-19 pandemic.
The complete vaccine development and approval pathway from research to licensure.